Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2022-02-03 00:00:00 ET · period of report 2022-02-01 · accession 0001209191-22-006757 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-02-03 | 2022-02-02 | VRTX | ALTSHULER DAVID | EVP, CSO, Gbl Research | M - OptEx | $86.52 | +4,660 | 70.4K | +7% | +$403.2K |
| DM | 2022-02-03 | 2022-02-02 | VRTX | ALTSHULER DAVID | EVP, CSO, Gbl Research | S - Sale+OE | $251.47 | -4,660 | 69.0K | -6% | -$1.17M |
| DM | 2022-02-03 | 2022-02-01 | VRTX | ALTSHULER DAVID | EVP, CSO, Gbl Research | A - Grant | $0.00 | +32.1K | 65.7K | +96% | $0 |
| D | 2022-02-03 | 2022-02-02 | VRTX | ALTSHULER DAVID | EVP, CSO, Gbl Research | M - OptEx | $86.52 | -4,660 | 0 | -100% | -$403.2K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-02-02 | M | A | 4,660 | $86.52 | 70,357 | D | — | — | |
| 2 | Common | Common Stock | 2022-02-02 | S | D | 300 | $254.46 | 65,697 | D | — | — | (F12) Open market sales reported on this line occurred at a weighted average price of $254.46 (range $254.34 to $254.58). (F6) Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. |
| 3 | Common | Common Stock | 2022-02-02 | S | D | 1,099 | $253.41 | 65,997 | D | — | — | (F11) Open market sales reported on this line occurred at a weighted average price of $253.41 (range $253.05 to $253.99). (F6) Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. |
| 4 | Common | Common Stock | 2022-02-02 | S | D | 900 | $252.10 | 67,096 | D | — | — | (F6) Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. (F10) Open market sales reported on this line occurred at a weighted average price of $252.10 (range $251.75 to $252.72). |
| 5 | Common | Common Stock | 2022-02-02 | S | D | 980 | $251.22 | 67,996 | D | — | — | (F9) Open market sales reported on this line occurred at a weighted average price of $251.22 (range $250.71 to $251.70). (F6) Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. |
| 6 | Common | Common Stock | 2022-02-01 | A | A | 8,166 | $0.00 | 41,755 | D | — | — | (F1) Represents earned performance shares with respect to a performance stock unit award granted on 02/06/2019 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2022 and the shares will vest on 02/24/2022. |
| 7 | Common | Common Stock | 2022-02-01 | A | A | 11,628 | $0.00 | 53,383 | D | — | — | (F2) Represents earned performance shares with respect to a performance stock unit award granted on 02/03/2021 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2022 and the shares will vest in installments beginning on 02/17/2022. |
| 8 | Common | Common Stock | 2022-02-01 | A | A | 12,314 | $0.00 | 65,697 | D | — | — | (F3) Restricted stock unit award that vests in installments beginning on 02/24/2023. |
| 9 | Common | Common Stock | 2022-02-02 | S | D | 500 | $247.73 | 69,857 | D | — | — | (F6) Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. (F5) Open market sales reported on this line occurred at a weighted average price of $247.73 (range $247.35 to $248.34). |
| 10 | Common | Common Stock | 2022-02-02 | S | D | 127 | $248.65 | 69,730 | D | — | — | (F6) Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. (F7) Open market sales reported on this line occurred at a weighted average price of $248.65 (range $248.46 to $249.34). |
| 11 | Common | Common Stock | 2022-02-02 | S | D | 754 | $249.97 | 68,976 | D | — | — | (F8) Open market sales reported on this line occurred at a weighted average price of $249.97 (range $249.61 to $250.33). (F6) Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. |
| 12 | Derivative | Stock Option (Right to Buy) | 2022-02-02 | M | D | 4,660 | $86.52 | 0 | D | $86.52 · — to 2027-02-02 | 4,660 Common Stock | (F13) Fully vested. |